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Negative cooperativity in NAD(P)H quinone oxidoreductase 1 (NQO1) 
Clare F. Megarity[a],Hoda Abdel-Aal Bettley[b], M. Clare Caraher[a],[b], Katherine A. Scott[b], Roger C. 
Whitehead[c], Thomas A. Jowitt[d], Aldo Gutierrez[e], Richard A. Bryce[b], Karen A. Nolan[b], Ian J. 
Stratford[b], David J. Timson*[a],[f] 
Abstract: NAD(P)H quinone oxidoreductase-1 (NQO1) is a 
homodimeric protein that acts as a detoxifying enzyme or as a 
chaperone/nanny protein. Dicourmarol interacts with NQO1 at the 
NAD(P)H binding site and can both inhibit enzyme activity and 
modulate the interaction of NQO1 with other proteins. We show the 
binding of dicoumarol and related compounds to NQO1 generates 
negative cooperativity between the monomers. This does not occur in 
the presence of the reducing co-factor, NAD(P)H, alone. Alteration of 
Gly150 (but not Gly149 or Gly174) abolished the dicoumarol-induced 
negative cooperativity. Analysis of the dynamics of NQO1 with the 
Gaussian network model indicates a high degree of collective motion 
by monomers and domains within NQO1. Ligand binding is predicted 
to alter NQO1 dynamics both proximal to the ligand binding site and 
remotely, close to the second binding site. Thus, drug-induced 
modulation of protein motion may contribute to the biological effects 
of putative inhibitors of NQO1. 
Introduction 
NAD(P)H quinone oxidoreductase (NQO1, DT-diaphorase, 
E.C. 1.6.5.2) is a homodimeric flavoprotein with one molecule of 
non-covalently bound flavin adenine dinucleotide (FAD) per 
monomer.[1] The enzyme’s two active sites are located at the 
interface between the two subunits and involve residues from both 
polypeptide chains.[1a] NQO1 is a detoxification enzyme with its 
main function being the obligate two-electron reduction of 
quinones to hydroquinones.[2] The enzyme is unusual in that it can 
use either NADH or NADPH in the first step of its catalytic process, 
the transfer of a hydride group to the FAD molecule.[1a, 3] The 
second step is the transfer of the hydride group from the reduced 
cofactor to the newly docked quinone substrate, but this can only 
occur once the NAD(P)+ has been released, hence the description 
of the mechanism as a “ping-pong” reaction.[1a, 3-4] It has been 
suggested that the two active sites in the enzyme act 
independently [1a]. However, in an early study of NQO1 from rat 
liver, enzyme kinetic analysis indicated non-equivalent active 
sites and negative cooperativity towards some inhibitors.[5]  
Recent work combining biophysical and computational methods 
has demonstrated considerable effects of mobility within the 
enzyme.  Although the C-terminal domain (CTD) is not directly 
involved in forming the active site, removal of this part of the 
protein dramatically reduces the affinity for FAD and, 
consequently, catalytic activity.[6] The binding of FAD to one active 
site reduces the affinity at the other.[7] This negative cooperativity 
of cofactor binding may have implications for catalysis and the 
binding of other ligands [8]. 
NQO1 has also been shown to have chaperone properties. It 
stabilises the tumour suppressor protein p53 and other short-lived 
proteins such as p73α and ornithine decarboxylase.[9] This 
stabilization phenomenon is NAD(P)H-dependent and inhibitors 
of NQO1, such as dicoumarol and curcumin, which compete with 
NAD(P)H, have been shown to promote p53 degradation.[9c, 10] 
The enzyme is overexpressed in some cancer cells and 
inhibition of NQO1 has been proposed as a cancer chemotherapy 
strategy. The increased NQO1 activity in these cells may be 
associated with enhanced drug detoxification, increased stress 
resistance and decreased susceptibility to p53-mediated 
apoptosis.[11] Dicoumarol has been shown to inhibit the growth of 
pancreatic cancer cells.[12]  However, this compound is not an 
ideal anticancer agent due to its off target effects which include 
anticoagulant and mitochondrial “uncoupling” activity.[13]  
Consequently a number of studies have focussed on identifying 
novel inhibitors of NQO1, often ones which are structurally similar 
to dicoumarol 1 (Scheme 1) or quinones, for example see 
reference [14]. Conversely, reduced NQO1 activity resulting from 
polymorphic forms of NQO1, the most common of which results 
in a proline to serine substitution at position 187, can result in 
genetic predisposition to certain types of cancer, presumably due 
to reduced cellular antioxidant activity.[15] This P187S variant has 
reduced affinity for FAD and increased susceptibility to proteolytic 
degradation.[6a, 6b, 16] 
The importance of NQO1 in detoxification, molecular 
pathology and as a potential drug target all mean that 
understanding the enzyme’s interaction with ligands is critical. 
The potential for cooperativity in the enzyme suggests 
communication between the active sites. These phenomena are 
likely to have effects beyond enzymology and may impact on 
NQO1’s cellular roles as a chaperone. Here, we demonstrate 
kinetic negative cooperativity of human NQO1 by dicoumarol and 
three structurally related inhibitors (compounds 1-4; Scheme 1). 
Overall, our results paint a picture of an enzyme in which 
modulation of protein motions mediates communication between 
the two active sites. 
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Scheme 1: The compounds used in this study. All four of these compounds 
have been shown to inhibit NQO1 in vitro and the growth of HT29 cells in 
culture. IC50 values have been reported previously.14 Compound 1 is 
dicoumarol. Compounds 2, 3 and 4 were designated AS1, AS3 and S4 in 
previous work.[14a, 14c] 
 
Results and Discussion 
Cellular inhibition of NQO1 results in lower p53 levels 
Previous studies have shown that dicoumarol (1) inhibits 
NQO1 in vivo and, consequently, reduces the amount of the 
apoptosis regulator p53.[10a, 14c, 17] Three new analogues of 1 have 
been described (2-4; Scheme 1) which also inhibit NQO1 in 
vitro.[14a] These inhibitors also reduce the amount of cellular p53 
in the presence and absence of etoposide (a p53 inducer) at 
concentrations similar to those required to achieve enzyme 
inhibition (Figure S1, S2, S3). The concentrations of 2-4 were 
below those which cause toxicity in the cell lines used.[14a, 14c] Thus, 
these newly identified inhibitors have promise for the 
pharmacological inhibition of NQO1 and associated reduction in 
p53 levels with reduced side-effects compared to 1. 
 
Human NQO1 shows negative cooperativity towards 
inhibitors, but not towards NAD(P)H 
In the 1970s, it was reported that rat NQO1 shows negative 
cooperativity towards some inhibitors, including 1.[5] More recently, 
negative cooperativity towards inhibitors has been observed in 
the functionally related proteins human NRH quinone 
oxidoreductase 2 (NQO2; EC 1.10.5.1) and Saccharomyces 
cerevisiae Lot6p (EC 1.5.1.39).[18] Here we find that recombinant 
human NQO1 showed negative cooperativity towards 1 and also 
towards 2-4: Hill plots of inhibition data revealed Hill coefficients 
of approximately 0.5 and ΔΔG values between 4.9 and 7.3 kJmol-
1 for all four compounds (Figure 1; Table 1). Interestingly no 
cooperativity was observed towards the substrates NADH and 
NADPH, despite 1-4 competitively inhibiting NQO1 with respect 
to these compounds[14a, 19] (Table 1; Figure S4). Negative 
cooperativity towards 1-4 was confirmed by direct binding 
experiments using isothermal titration calorimetry. The binding of 
ligands to the dimeric NQO1 was best fitted to a “sequential 
binding sites” model (Figure S5). 
 
Negative cooperativity in NQO1 can be disrupted by a single 
amino acid substitution 
Negative cooperativity implies that there is some form of 
communication between the active sites. This can be mediated by 
conformational changes or through alterations in the mobility of 
elements of the protein’s structure.[20] Since glycine residues 
permit the greatest flexibility of a polypeptide chain, we 
concentrated on these residues as possible places to disrupt 
communication between the active sites.[21] We focussed on three 
residues, Gly149, Gly150 and Gly174. These amino acids are in 
proximity to the dicoumarol binding site and Gly174 breaks α-helix 
α4 (following the notation of Faig et al.)[14g] which spans the 
distance between the active sites (residues 163-180).[22] 
Alteration of Gly149 to serine resulted in no change in the Hill 
coefficient for ligand 1. When Gly174 was changed to serine, the 
purified protein was noticeably less yellow than the wild-type 
(suggesting a failure to bind FAD) and no activity could be 
detected. Supplementation of the reaction with FAD restored 
activity, but the Hill coefficient was similar to that of wild-type. 
However, altering Gly150 to serine increased h to almost one in 
both the presence and absence of exogenous FAD (ΔΔG 
approximately 1 kJmol-1) (Figure 1b and Table 1). Like the wild-
type protein, all three glycine-to-serine substitutions showed no 
cooperativity towards NADH (Figure S4 and Table 1). The serine-
substituted variants showed similar stability towards limited 
proteolysis (Figure S6) and only slightly increased susceptibility 
to thermal denaturation (as judged by differential scanning 
fluorimetry; Table 1). 
 
Elastic network modelling of NQO1 supports a dynamical 
basis for negative cooperativity 
In order to explore the structural basis for these observations, 
with a particular focus on the modulation of cooperativity within 
NQO1, we described the enzyme using a coarse grained 
dynamical approach, namely the Gaussian network model 
(GNM).[23] Such elastic network models have been widely used in 
characterising the global dynamics and allostery of proteins and 
their complexes.[24] In a GNM of a protein, the residues, along with 
cofactor and ligand where applicable, are connected by harmonic 
springs. The low frequency modes of motion derived from the 
resulting connectivity matrix can indicate key mechanical and 
functional features of a protein.  
Here we consider GNM analysis based on the X-ray structure 
of NQO1 in complex with ligand 1, with corresponding PDB code 
2F1O.[22] Each monomer of NQO1 comprises a large N-terminal 
domain (NTD) with flavodoxin topology, involving residues 1–223; 
and a smaller CTD, from residues 224–273; FAD and ligand bind 
at the interface between the monomers (Figure 2a). Overall, the 
NQO1 dimer becomes slightly more compact on binding 1-4, as 
demonstrated by analytical ultracentrifugation (Figure S7, Table 
S1). For NQO1, computation of B-factors via the Gaussian 
network model indicates areas of mobility; these indicate higher 
flexibility around residues 240 - 248 in each monomer. This region 
corresponds to the two short helices, α8, of the CTD (Figure 2a,b). 
Other regions of high B-factor value involve amino acids at the 
α1-β2 junction (31 – 35), loop L3 (58 – 68), loop L9 (230 – 235), 
as well as CTD helix α5 (197 – 211). These predicted high B-
factor regions correspond well to those found experimentally 
(Figure 2a,b). 
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Figure 1.  Human NQO1 showed negative cooperativity towards dicoumarol and related compounds. (a) Hill plots for NQO1 enzymatic activity in the presence of 
compounds 1-4. In this type of plot, log10(v/v0-v) is plotted against log10[Inhibitor], where v0 is the maximal or uninhibited rate. In such plots, the gradient of the line 
equals –h, such that positive cooperativity is indicated when h > 1.0 and negative cooperativity when h < 1.0. When h = 1.0, there is no cooperativity.[25] This 
method has been widely used to detect cooperative behaviour of enzymes towards their inhibitors (for example, to detect positive cooperativity in the inhibition of 
fructose 1,6-bisphosphatase by AMP [26], to detect negative cooperativity in the fosmidomycin inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase,[27] 
and to show the lack of cooperativity in the inhibition of alkaline phosphatase by L-tryptophan[28]). Each point represents the mean of three separate 
determinations, the error bars are standard deviations of these means and the lines are linear best fits to the data. Hill coefficients are given on the graphs. (b) Hill 
plots were constructed for the glycine to serine variants with 300 μM NADH, 70 μM DCPIP and varying concentrations of dicoumarol. Reactions were measured 
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at 37 °C using 5 nM G149S-NQO1, 5 nM and 8 nM G150S-NQO1; the activity of G174S-NQO1 was too low to measure in the absence of additional FAD. These 
plots were used to estimate the Hill coefficient (h). Each point represents the mean of three separate determinations and the error bars show the standard error of 
these means; triplicate Hill plots were constructed, one representative plot with a median value of h shown. This was repeated in excess FAD for each enzyme 
(each enzyme stock was pre-diluted using FAD containing buffer such that it was 10x the concentration of active sites in the diluted stock; enzyme concentrations 
were decreased to account for the higher activity in the presence of FAD:  G149S-NQO1, 2.5 nM; G150S-NQO1, 5 nM; G174S-NQO1, 10 nM). 
 
 
Table 1:  Kinetic and stability parameters for wild-type NQO1 and glycine to serine substituted variants.   
 
hdicoumarol 
(ΔΔG kJmol-1) 
hNADH 
(ΔΔG kJmol-1) 
Km,appNADH 
µM 
kcat,app 
s-1 
kcat/Km 
μM-1s 
Tm 
°C 
-FAD +FAD 
Wild type 
0.56 ±0.01 
(4.9) 
0.47 ±0.09 
(6.1) 
1.05 ±0.05 
(-0.5) 
240 ±34 186 ±12 0.78±0.16 49.17 ±0.47 
NQO1- 
G149S 
0.39 ±0.05 
(7.3) 
0.47 ±0.03 
(6.1) 
0.99 ±0.09 
(0.1) 
570 ±161 135 ±21 0.24±0.10 46.10 ±0.53 
NQO1- 
G150S 
0.90 ±0.19 
(1.0) 
0.94 ±0.06 
(0.6) 
1.07 ±0.08 
(-0.7) 
265 ±64 126 ±14 0.48±0.17 47.57 ±0.40 
NQO1- 
G174S 
Activity too low 
0.57 ±0.05 
(4.7) 
1.09 ±0.02 
(-0.9) 
307 ±35 78 ±4 0.25±0.04 46.43 ±0.32 
 
Kinetic measurements used wild type NQO1 (3 nM dimer), NQO1- G149S (3 nM dimer), NQO1-G150S (3 nM dimer) and NQO1-G174S (20 nM dimer) with 70 μM 
DCPIP at 37 °C.  Non-enzymatic background rates were measured in triplicate at each concentration of NADH and 70 μM DCPIP at 37 °C in 50 mM phosphate 
buffer pH 7.4 and the mean of these subtracted from the rates obtained from the linear section at the beginning of each progress curve with enzyme included (also 
in triplicate).  Melting temperatures (Tm) were determined (in triplicate) by DSF.
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Figure 2: (a) Experimental B-factors for atoms of crystal structure of NQO1 
(largest values in red),[22] FAD and ligand 1 in green; (b) Comparison of 
computed (black) and experimental (blue) B-factor values across NQO1 
residues. Magnitude of motion for modes (c) k=1; (d) k=2; and (e) k=3 (red, most 
mobile; blue, least mobile). Dynamic domains for (f) k=1; (g) k=2; and (h) k=3. 
The domains are separated by the signs of eigenvectors and colored red (+) 
and blue (-) respectively. 
 
 
 
Using the Gaussian network model, we consider the predicted 
fluctuation profiles of the most global modes of motion for apo 
NQO1, with ligand 1 removed from both sites. We observe that 
these slowest frequency modes appear to represent strongly 
collective motions of NQO1: for the lowest frequency mode, 
labelled k=1, the higher amplitude motions of the protein (red 
regions in Figure 2c) appear to belong to the NTD regions of the 
monomers. We note that blue region in Figure 2c indicates lower 
motion and defines a hinge region. For mode k=2, the mobility of 
NQO1 also involves CTD residues belonging to the α8 helices of 
both monomers (Figure 2d). For the k=3 mode, only one of the 
two α8 helices is engaged (Figure 2e). In terms of the direction of 
these motions, the k=1 and k=2 modes involve cross-monomer 
antisymmetric movement of NQO1 (Figure 2f,g) whereas for k=3, 
the monomers appear to librate separately in a wagging motion 
(Figure 2h). For all three modes, however, the interface for 
anticorrelated domain dynamics intersects with both NQO1 active 
sites (Figure 2f-h).  
We may quantify the non-local nature of these soft modes by 
computing their collectivity, Ωk (see Methods).[29] In all cases, the 
modes are global motions, with collectivity values of 0.62, 0.52 
and 0.46 for the respective k=1, k=2 and k=3 modes, ie. for the 
k=1 mode, 62% of the NQO1 residues are involved in these 
modes respectively (Figure S8). The collectivity of other modes 
dimishes only slowly with increased frequency, eg. Ωk has a value 
of 0.33 for mode k=20 (Figure S8). 
Next, we considered the effect on the dynamics of NQO1 by 
introducing ligand 1 at one of protein’s two active sites. For the 
three softest modes of the NQO1 complex, the magnitude and 
direction of the motions remain qualitatively similar to that of the 
apo protein modes shown in Figure 2c-h. Nevertheless, there are 
differences in the detailed motion of the protein predicted on 
ligand association: as perhaps might be expected, there is a 
significant decrease in mode motion of active site residues in the 
vicinity of the bound ligand (Figure 3a); for example, for k=1, this 
is most notable for residues 115 - 150; this region includes active 
site residue Tyr128, the mobility of which drops by 62% on ligand 
binding (Figure 3a).  
 
Figure 3. (a) Difference in magnitudes of motion on ligand 1 binding (computed 
as apo – complexed), for modes k=1 (black), 2 (blue) and 3 (red); (b) Difference 
in mode motion on ligand 1 binding of summed ten slowest modes of motion.  
 
 
 
By contrast, in some parts of the enzyme, there is an increase 
in mode motion on ligand binding. For k=1, this occurs mainly at 
NTD helix α5 that traverses NQO1 (residues 196 – 210, Figure 
3a); the spatial location of α5 is shown in Figure 2a. For k=2, 
increasing mobility on ligand association is found at helices α1 
(residues 11 - 44) and again at α5 (Figures 2a and 3a). Finally, 
for the k=3 mode, residues 51 – 91 and 150 – 164 are more 
mobile on complexation (Figure 3a), The first region includes loop 
L3 (Figure 2a) which is highlighted as a flexible region from B-
factors (Figure 2b) and from previous work.[6a, 6c] Interestingly, 
residues 15 – 164 correspond to loop L6 in the second, 
unoccupied binding site (Figure 2a). These amino acids are 
remote to the binding site, although we note there is an equal and 
opposite effect from mode 2. Overall, considering the cumulative 
contribution of the 10 slowest modes (Figure 3b), on binding of 1, 
the motion is damped around the ligand binding site and a 
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neighbouring shell of residues centred around Gly180 and 
Phe181. By contrast, there is an increase in flexibility around 
amino acids 242 – 251, i.e. helix α8 in the CTD. 
To further probe the sensitivity of amino acids in NQO1 to 
receiving and propagating mechanical signals, we applied 
perturbation-response scanning (PRS) to the Gaussian network 
model of the protein.[30] From PRS analysis, a range of residues 
across NQO1 appear to be sensitive to perturbation (black, Figure 
4), with peaks in signal profile at secondary structure elements α1, 
α7, β4-L6 and α5 in the NTD and α8 in the CTD. This pattern is 
broadly reflected by the profile of residues which are effective in 
propagating signal through the protein (red, Figure 4). Clearly, 
NQO1 forms a highly collective dynamic network of amino acids, 
capable of responding to ligand binding and communicating that 
response through the protein.  
Specifically, PRS suggests that the α8 helix, residues 242-
251 of the CTD, would respond (Figure 4) to the increase in mode 
motion on ligand binding (Figure 3b) and would be capable of 
propagating this signal remotely throughout the protein, including 
to regions such as loop L6 near the second binding site, 
potentially impairing binding of a second ligand at that site.  
Figure 4. Magnitude of perturbation (black) and response (red) signal of 
receiver and propagator residues respectively in apo NQO1 model.  
 
 
 
Given this highly interconnected network of residues in NQO1, 
sensitive to ligand binding, it is perhaps surprising that only the 
G150S variant led to abrogation of negative cooperativity, 
whereas G149S and G174S variants did not (Table 1). The slow 
modes of NQO1 computed from the Gaussian network model 
indicate that residues Gly149 and Gly150, and to a lesser extent, 
Gly174, lie in regions of near-zero mode motion (Figure 3b); 
residues with low motion have been shown in elastic network 
studies of other proteins to point towards significant hinge or 
functional residues within a macromolecule.[31] Indeed, all three 
glycines lie near the ligand binding site (Figure 5a) and the 
backbones of Gly149 and Gly150 play a specific role in hydrogen 
bonding with the isoalloxazine ring of FAD. However, from 
inspection of the NQO1/1 crystal structure, we note that 
perturbation to serine of Gly150, but not Gly149 or Gly174, would 
directly obstruct the substrate/inhibitor binding site (Figure 5b). 
This in turn could lead to displacement of immediately neighboring 
residues (Tyr126, Tyr128), second shell residues (Gly180, 
Phe181) and beyond this, the CTD helix α8 residues 242 - 251 
(Figure 5b), interfering with the negatively cooperative 
communication between active sites. 
 
 
Figure 5. (a) Location of Gly149, Gly150 and Gly174 at active site of NQO1 
(monomers coloured red and blue; FAD and 1 in green). (b) Spatial relationship 
of Gly149 and Gly150 to promixal residues linked to inter-active site 
communication.  
Conclusions 
These findings have considerable implications for the function 
of the protein in vivo and its exploitation as an anti-cancer drug 
target. Our studies imply that, in addition to adopting a correctly 
folded three-dimensional structure, NQO1 displays highly 
collective inter-domain and inter-monomer dynamics. This 
coupled network of amino acids is sensitive to ligand binding and 
can be disrupted by a single amino acid change, with functional 
consequences for the protein. Therefore, it is possible that the 
cancer-associated polymorphisms exert their pathogenic effect, in 
part, through alteration of the dynamics of the protein. This 
hypothesis is supported by recent studies demonstrating that the 
P187S variant of NQO1 is more likely to populate partially 
unfolded states.[6a, 6c, 16a-c] This mutation site is found at the 
monomer-monomer interface and was able to interfere remotely 
with the structure and dynamics of the FAD binding site, loop L3 
and the CTD in particular, again suggesting a strongly coupled 
dynamical communication network within NQO1.  
There are also implications for cells expressing wild-type 
NQO1. Moscovitz et al. have raised the intriguing notion that 
NQO1-mediated protein stability may be linked to cellular 
metabolic status: in particular a regulatory role for cellular FAD 
has been proposed.[32] In addition, the ability of NQO1 to prevent 
degradation of proteins via the 20S proteosome is NADH-
dependent which also suggests an underlying redox sensing 
mechanism for the chaperone function of NQO1.[10a] Coumarin-
based inhibitors such as dicoumarol (1) compete with NADH for 
binding to NQO1 and thereby target p53 for degradation. Although 
the precise mechanism for this is unclear, it is likely to involve 
direct interactions between NQO1 and p53.[33] Negative 
cooperativity occurs only with inhibitors and not with NAD(P)H. 
One consequence of negative cooperativity is to dampen the 
responsiveness of a system. Some enzymes involved in 
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signalling exhibit negative cooperativity and, consequently, are 
switched on over a wide range of substrate concentrations.[34] It is 
possible that a similar situation occurs here: NQO1’s negatively 
cooperative response to inhibitors may result in inhibition of the 
p53 interaction over a wide range of concentrations. Therefore, 
the most pharmacologically useful NQO1 inhibitors may be those 
which maximise both affinity and negative cooperativity. 
It is interesting to speculate on the evolutionary significance 
of negative cooperativity in NQO1. To date, no cellular 
metabolites have been identified which inhibit NQO1 in vivo. All 
known inhibitors are either exogenous drugs or toxins.  However, 
the existence of strong negative cooperativity in this enzyme 
suggests that it confers some selective advantage. It may be 
important in the mechanism of protein chaperoning, as noted 
above. Another possibility is that the negative cooperativity in FAD 
binding coincidentally affects interaction with inhibitors such as 
dicoumarol.[7] If this was the case, it seems likely that the negative 
cooperativity is important in the protein's redox sensing role 
potentially enabling it to act over a wide range of cellular FAD 
concentrations. 
Experimental Section 
Reagents, chemicals and NQO1 inhibitors: Unless otherwise stated, all 
reagents and chemicals were supplied by Sigma Aldrich (Poole, Dorset, 
UK). Dicoumarol was dissolved to a concentration of 25 mM in fresh 0.13 
M sodium hydroxide. Etoposide was dissolved to a concentration of 10 mM 
in DMSO. The NQO1 inhibitors (Scheme 1) were dissolved in DMSO to 
give a final concentration of 25 mM. Compounds 2-4 were prepared as 
described previously.[14a] 
 
Cell lines and cell culture: Cells were maintained at 37 °C in exponential 
phase in a humidified incubator with 5% CO2. HCT116 colon carcinoma 
cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% (v/v) heat-inactivated foetal calf serum and 2 mM 
L-glutamine. MCF10A breast epithelial cells were maintained in DMEM/F-
12 (1:1) containing L-glutamine (2 mM), horse serum (5%), epidermal 
growth factor (20 µg/mL), hydrocortisone (0.5 µg/mL), cholera toxin (0.1 
µg/mL), insulin (10 µg/mL) and penicillin/streptomycin (1%). Human 
umbilical vein endothelial cells (HUVECs) were obtained from TCS 
CellWorks (Buckingham, UK) and cultured as per the supplier’s 
instructions. Cells were used between passages 2-16 (HCT116 and 
MCF10A) and 2-8 (HUVECs). 
 
Western blot analysis of p53 levels: Exponentially growing cells were 
seeded at 105 cells/well in six well plates, left to adhere overnight, then 
treated with or without 10 µM etoposide for 24 h prior to treatment with 50, 
100, 200 or 400 µM of each inhibitor and incubated for four hours. Cells 
were harvested by scraping into lysis buffer (50 mM Tris-HCl (pH 7.4), 120 
mM NaCl, 5 mM EDTA, 0.5% v/v Nonidet P-40, 1 mM dithiothreitol, 1 mM 
phenylmethanesulphonyl fluoride, 2 mM sodium orthovanadate, 2 mM 
sodium fluoride, 20 mM β-glycerolphosphate, 5 mM sodium 
pyrophosphate, and 1 mg/ml Protease Inhibitor Cocktail tablet (Roche, 
UK). Samples were then sonicated on ice and the protein concentration of 
each was estimated using the BCA assay. For each sample, 40 µg protein 
was loaded and electrophoresed. p53 antibody (DO-1, Insight 
Biotechnology, Middlesex, UK) was used to assess p53 protein levels, 
while β-actin or tubulin antibodies were used as loading controls. Primary 
antibodies were then detected using the appropriate HRP-conjugated 
secondary antibody and bands were visualized using the ECL detection 
system (GE Healthcare, Buckinghamshire, UK). Exponentially growing 
HUVECs were seeded at (2.5 x105 cells/well) in six well plates and left to 
adhere overnight, before exposure to 10 Gy ionizing radiation (250 kV X-
rays). The cells were then incubated for 4 h with and without the inhibitor 
before being harvested and probed for p53 as described above. 
 
Measurement of NQO1 kinetics and inhibition: Recombinant human 
NQO1 was either a gift from Professor David Ross and Dr David Siegel or 
prepared as described previously[16a]. Reduction of 
dichlorophenolindophenol (DCPIP) by NADH was measured 
spectrophotometrically at 600 nm at 37 °C in 50 mM sodium phosphate 
buffer (pH 7.4). For measurement of wild-type NQO1 with NAD(P)H and 
inhibition of wild-type NQO1 by 1-4 in the presence of 200 μM NADH a 
Cary 100 Scan UV-visible spectrophotometer was used with 40 μM DCPIP 
and 40 μM NQO1 in a total reaction volume of 900 μl. For inhibition of 
glycine to serine variant forms of NQO1 by 1 a Multiskan Spectrum 
platereader (Thermo Scientific) was used with 300 µM NADH, 70 µM 
DCPIP, 3-20 nM NQO1 and 0.9 μM lysozyme in a total volume of 200 
μl .[16a] Reactions were initiated by the addition of NQO1 and rates were 
measured for 2 min at 37 °C. Data were fitted to the Michaelis-Menten and 
Hill equations[35] using GraphPad Prism 5.0. 
For inhibition experiments, compounds 1-4 were dissolved in 
DMSO/0.13M NaOH and diluted such that the final concentration of these 
solvents was 0.5% (v/v). Inhibition data were analysed by Hill plots in which 
log10(v/v0-v) is plotted against log10[Inhibitor], where v0 is the rate of the 
uninhibited reaction. In such plots, the gradient of the line equals –h, such 
that positive cooperativity is indicated when h > 1.0 and negative 
cooperativity when h < 1.0 [25a, 35]  Cooperativity was also assessed using 
the method of Forsén and Linse.[36]  This method enable the estimation of 
difference in free energy of binding between the high and low affinity states 
of the protein (ΔΔG).  It makes a number of assumptions.  First that 
cooperativity can be represented by two equilibria:  K1, the dissociation 
constant for the ligand and the unliganded enzyme and K2, the dissociation 
constant for the ligand and enzyme already bound to one ligand molecule 
(i.e. these are “macroscopic” binding constants which reflect the overall 
ligand occupancy of the protein).  In the case of negative cooperativity, K2 
will be greater than (i.e. lower affinity) than K1.  Second, that in the 
unliganded enzyme, the affinities of the two binding sites for the inhibitor 
are equal (i.e. that the “microscopic” binding constants for the two active 
sites are the same).  This would be expected in a homodimeric enzyme 
like NQO1.  However, it should be noted that there is no positive evidence 
in favour of this assumption.  Thus, the ΔΔG values reported here should 
be seen as minimum values. 
The Hill coefficient is related to these two equilibrium constants by the 
equation: 
𝒉𝒉 = 𝟒𝟒�𝑲𝑲𝟐𝟐 𝑲𝑲𝟏𝟏⁄
𝟏𝟏 + 𝟐𝟐�𝑲𝑲𝟐𝟐 𝑲𝑲𝟏𝟏⁄  
The difference in free energies can be calculated according to the 
equation: 
∆∆𝑮𝑮 = −𝑹𝑹𝑹𝑹 𝐥𝐥𝐥𝐥𝐥𝐥𝒆𝒆 𝟒𝟒𝑲𝑲𝟐𝟐𝑲𝑲𝟏𝟏  
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Where, R is the universal gas constant and T is the absolute (Kelvin) 
temperature. 
 
Ultracentrifugation: NQO1 was buffer exchanged and further purified on 
a Superdex 200 10/30 gel filtration column (GE-Lifesciences) in PBS. Peak 
fractions were pooled and diluted in buffer with or without the addition of 
inhibitors to a final concentration 15 µM. Samples were then loaded into a 
two-sector Epon filled centerpiece covered with quartz glass windows and 
centrifuged at 45000 rpm at 20 °C. Sedimentation was monitored every 90 
s using absorbance at 450 nm until full sedimentation had been reached. 
The data were analysed using Sedfit software.[37] 
 
Isothermal titration calorimetry of ligand binding: Ligand binding to 
NQO1 was studied at 25 °C using a VP-ITC microcalorimeter (Microcal Inc, 
MA). Data acquisition and analysis were carried out using ORIGIN 7.0 
(Microcal Inc., MA). Ligand binding was quantified by fitting the evolved 
heat per injection to the standard Wiseman equation. Fitting of the binding 
isotherm was carried out through multiple iterations until a minimum χ2 
value was obtained. Reported values are the average of at least three runs. 
NQO1 monomer concentration was chosen so as to give c values in the 
100-300 range (typically 3-5 µM). Both NQO1 and ligands were dissolved 
in 50 mM phosphate pH 7.5 buffer containing 5 mM FAD and 2.5% (v/v) 
DMSO. 
 
NQO1 protein stability: Differential scanning fluorimetry was performed 
as described previously, taking advantage of the increase in the natural 
fluorescence of the FAD molecules which occurs when the cofactor is 
released as the protein denatures.[18, 38] Limited proteolysis with increasing 
concentrations of chymotrypsin (0, 5, 10, 35, 60, 90, 360, 630 nM) was 
performed with wild-type and variant NQO1 protein (10 μM dimer) which 
had been pre-incubated at 37 °C for 15 min. The reaction was allowed to 
proceed for 30 min after which time it was stopped by addition of an equal 
volume of tris-tricine SDS loading buffer (12 % (w/v) SDS; 6 % (w/v) DTT; 
30 % (v/v) glycerol; 150 mM Tris/HCl pH 7). Reactions were analysed 
using tris-tricine SDS PAGE.[39] 
 
Elastic network modelling: For generating the GNM models, the 
coordinates of the crystal structure of NQO1 bound to ligands 1 were taken 
from PDB code 2F1O[22] using chains B and D. FAD was modelled by 
springs centred on atoms C7, N5, N3, C1’, C4’, P, PA, C4b and N9a. The 
ligand was modelled by atoms C5, C1 and C15. The Cα atoms of the amino 
acids, and these ligand atoms where relevant, were used to build the 
Kirchhoff connectivity matrices Γ using a cutoff rc of 7.3 Å. For N residues 
in a molecular system, diagonalization of Γ provides N-1 modes; the 
resulting modes k of eigenvector uk with the smallest eigenvalue λk 
correspond to softest and most cooperative motions within the molecular 
system. Contribution to motion of mode k is computed as 〈∆𝑹𝑹𝒊𝒊 ∙ ∆𝑹𝑹𝒋𝒋〉𝒌𝒌 =(𝟑𝟑𝒌𝒌𝑩𝑩𝑹𝑹/𝜸𝜸)[𝝀𝝀𝒌𝒌−𝟏𝟏𝒖𝒖𝒌𝒌𝒖𝒖𝒌𝒌𝑹𝑹]𝒊𝒊𝒋𝒋 where ∆𝑹𝑹𝒊𝒊 is the Gaussian fluctuation in position of 
residue i, 𝒌𝒌𝑩𝑩 is Boltzmann’s constant, T is temperature and γ is the network 
force constant. Differences in mode motion are computed as the square 
displacement of residues driven by a given mode of complexed NQO1 
subtracted from that of apo NQO1. Following Brüschweiler,[29] the level of 
collectivity, 𝛀𝛀𝒌𝒌 , for a mode k is defined as 𝛀𝛀𝒌𝒌 = (𝟏𝟏/
𝑵𝑵)𝒆𝒆𝒆𝒆𝒆𝒆�−∑ 𝒖𝒖𝒌𝒌,𝒊𝒊𝟐𝟐𝒊𝒊 𝒍𝒍𝒍𝒍�𝒖𝒖𝒌𝒌,𝒊𝒊𝟐𝟐 �� for N residues i. GNM analysis was performed 
using the iGNM 2.0 conformational dynamics interface and database.[30b] 
Perturbation response scanning[31] is a method to compute the 
influence/sensitivity that each residue has on/to every other residue. 
Based on linear response theory, PRS is achieved by exerting a force of a 
given magnitude on the network, one residue at a time, and observe the 
response of the overall network. PRS30 was used to identify the most 
sensitive residues of NQO1. 
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